Acurx Pharmaceuticals (ACXP) Other financing activities (2020 - 2024)
Acurx Pharmaceuticals' (ACXP) quarterly Other financing activities came in at $210199.0 in Q1 2024, down 90.53% quarter-over-quarter from $2.2 million in Q4 2023.
Powered by 
Analysis
Acurx Pharmaceuticals (ACXP) Other financing activities (2020 - 2024) Analysis & Trends
Acurx Pharmaceuticals (ACXP) has reported Other financing activities for 3 consecutive years, with $210199.0 the latest figure, recorded in Q1 2024.
- For the quarter ending Q1 2024, Other financing activities changed N/A year-over-year to $210199.0; the trailing twelve-month figure through Dec 2024 stood at $210199.0 (down 90.53% YoY), and the FY2025 full-year result was $1.4 million, up 547.26% from the prior year.
- Other financing activities slipped to $210199.0 in Q1 2024 per ACXP's latest filing, from $2.2 million in the prior quarter.
- Across five years, Other financing activities topped out at $2.2 million in Q4 2023 and bottomed at $210199.0 in Q1 2024.
- Historically, Other financing activities has averaged $961666.3 across 3 years, with a median of $455874.0 in 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn |
| 10 | Acurx Pharmaceuticals | 6.65 Mn | 6.65 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2024 | 210,199.00 |
| Dec 31, 2023 | 2.22 Mn |
| Sep 30, 2020 | 455,874.00 |